{
    "clinical_study": {
        "@rank": "106096", 
        "brief_summary": {
            "textblock": "The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed\n      setting.  There is no standard treatment, and the few small studies that have been conducted\n      have reported dismal outcomes.  The purpose of this study is to pilot the use of EPOCH plus\n      rituximab in previously treated AIDS-related lymphoma.  Clinical endpoints of the study\n      include toxicity and response.  Progression-free and overall survival will be measured.\n      Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation,\n      c-myc and EBV when possible."
        }, 
        "brief_title": "EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma", 
        "completion_date": {
            "#text": "May 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "AIDS Related Lymphoma", 
            "Non Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, AIDS-Related"
            ]
        }, 
        "detailed_description": {
            "textblock": "The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed\n      setting.  There is no standard treatment, and the few small studies that have been conducted\n      have reported dismal outcomes.  The purpose of this study is to pilot the use of EPOCH plus\n      rituximab in previously treated AIDS-related lymphoma.  Clinical endpoints of the study\n      include toxicity and response.  Progression-free and overall survival will be measured.\n      Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation,\n      c-myc and EBV when possible."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA:\n\n        Aggressive CD20 + NHL confirmed by Pathology, DCS.\n\n        HIV + serology.\n\n        All stages (I-IV) of disease.\n\n        NHL previously treated with up to two chemotherapy regimens and evaluable disease.\n\n        Age greater than or equal to 18 years.\n\n        Laboratory test: (Abnormalities are allowed if due to organ involvement by lymphoma).\n\n        Creatinine less than or equal to 1.7.\n\n        Bilirubin must be less than 2.0 mg/dl, or total bilirubin less than or equal to 3.7 mg/dl\n        with direct fraction less than or equal to 0.2 mg/dl and indirect fraction of less than or\n        equal 3.5 mg/dl in patients for whom these abnormalities are felt to be due to protease\n        inhibitor therapy.\n\n        AST and ALT less than or equal to 3 times ULN (AST and ALT less than or equal to 6 times\n        ULN for patients on hyperalimentation for whom these abnormalities are felt to be due to\n        the hyperalimentation).\n\n        ANC greater than or equal 1000/mm(3).\n\n        Platelets must be greater than or equal to 75,000/mm(3) (patients with ITP platelets\n        greater than or equal to 30,000/mm(3).\n\n        Signed informed consent and Durable Power of Attorney.\n\n        EXCLUSION CRITERIA:\n\n        Pregnancy or nursing.\n\n        History of clinical heart failure or symptomatic ischemic heart disease.\n\n        Serious underlying medical condition or infection other than HIV that would contraindicate\n        EPOCH.\n\n        Concurrent anti-retroviral therapy during EPOCH therapy.\n\n        Primary CNS lymphoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00019253", 
            "nct_id": "NCT00001563", 
            "org_study_id": "970040", 
            "secondary_id": "97-C-0040"
        }, 
        "intervention": [
            {
                "description": "N/A", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "rituximab", 
                "intervention_type": "Biological"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "EPOCH regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "N/A", 
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Cytarabine", 
                "Methotrexate", 
                "Rituximab", 
                "Doxorubicin", 
                "Etoposide", 
                "Prednisone", 
                "Vincristine", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HIV Lymphoma", 
            "Interleukin-12", 
            "Cytokines", 
            "Immunomodulation", 
            "Therapy"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1997-C-0040.html"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Wyndham H Wilson, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Toxicity and activity of EPOCH during and at the completion of study treatment", 
            "safety_issue": "Yes"
        }, 
        "reference": [
            {
                "PMID": "2536124", 
                "citation": "Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding PA. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989 Feb 3;261(5):719-24."
            }, 
            {
                "PMID": "7950915", 
                "citation": "Sparano JA, Wiernik PH, Strack M, Leaf A, Becker NH, Sarta C, Carney D, Elkind R, Shah M, Valentine ES, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma. 1994 Jul;14(3-4):263-71."
            }, 
            {
                "PMID": "1672911", 
                "citation": "Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991 Apr 6;337(8745):805-9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Molecular markers of drug resistance and lymphomagenesis in tumor tissue at the beginning of study treatment", 
            "safety_issue": "No"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1996", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "National Institutes of Health Clinical Center, 9000 Rockville Pike": "38.985 -77.095"
    }
}